OwlTail

Cover image of Khosla Ventures

Khosla Ventures

15 Podcast Episodes

Latest 25 Sep 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Nextdoor SPAC | KVSB Stock | Khosla Ventures Acquisition Co. II | The Neighborhood App

WOLVES OF INVESTING

Nextdoor is in the process of merging with a SPAC called  Khosla Ventures Acquisition Co. II (KVSB). Accounts managed by Cathie Wood's Ark Invest are participating in the PIPE. The business combination is expected to close in the 4th quarter of 2021 and the ticker is expected to change to KIND. In this video, I go over my bull and bear case for Nextdoor stock. Check out my Patreon! https://www.patreon.com/wolvesofinvesting 💯 Join my free Discord: https://discord.gg/HGg4Ux2xR2 🚀🚀🚀 Sign up for M1 Finance today - We both get $50! 💲💲💲 https://m1.finance/zI26ef2V7_To Sign up for Webull - We both get free stocks! 💹 https://act.webull.com/ve/fBNoioDbGq9N/cmw/inviteUs/main This podcast is a rebroadcast of a video that originally aired on YouTube at Wolves Of Investing. DISCLAIMER: I'm not a financial advisor and this is not financial advice. This podcast is based on my opinion, provided "as-is", and for entertainment purposes only.--- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

14mins

12 Jul 2021

Episode artwork

Career Success with Irene Au, Operating Partner at Khosla Ventures - Issue #259

Invincible Career - Claim your power and regain your freedom

Listen now | Irene Au shares advice from her Silicon Valley experiences. Irene has been one of the most successful Design Leaders that I’ve known. She uses that wisdom at Khosla Ventures now.  This is a public episode. Get access to private episodes at newsletter.invinciblecareer.com/subscribe

28mins

17 Mar 2021

Similar People

Episode artwork

Nita Sommers, Khosla Ventures, on digital health’s transformation in three decades

The Pulse by Wharton Digital Health

Nita Sommers is an Operating Partner at Khosla Ventures focused on health care. Nita has spent over 20 years working in the health technology sector, with a passion for early-stage, high growth companies transforming health care. She was an early member of the R&D team at athenahealth, which went public in 2007. Additionally, she was one of the first executives at Castlight Health and later managed the company’s IPO in 2014. At Castlight Health, Nita led the company’s early sales efforts and later ran strategy, business development, corporate development and investor relations.  Most recently, she was President of Honor, where she was responsible for all aspects of growth including sales, marketing, customer success, business development and corporate development. In addition to her work at start-ups, she also spent several years consulting with McKinsey’s health care practice and working across a number of healthcare industry sectors while with McKesson. Nita enjoys working with early stage companies on growth strategy and execution, including product strategy, commercial strategy, sales management, business development and organizational development. Nita has an M.B.A. from Stanford Graduate School of Business and a B.A. from Harvard University. In this episode we discussed: Nita’s experience leading, exiting, and advising first-wave (1990s: athenahealth), second wave (2000s: Castlight) and third+ wave (2010+: Honor, others) digital health companies spanning three decades of health tech What we can learn from these companies’ ascent, as history repeats itself: finding unmet need in a large market, narrowing in on a core set of business challenges, and proving value, not just scaling for scale’s sake What makes the Operating Partner role unique in venture capital, and why her position at Khosla Ventures is distinctive across the healthcare fundraising landscape Tactical advice to women on breaking the glass ceiling as an executive or venture partner

46mins

20 Jan 2021

Episode artwork

Nita Sommers, Khosla Ventures, on digital health’s transformation in three decades

The Pulse by Wharton Digital Health

Nita Sommers is an Operating Partner at Khosla Ventures focused on health care. Nita has spent over 20 years working in the health technology sector, with a passion for early-stage, high growth companies transforming health care. She was an early member of the R&D team at athenahealth, which went public in 2007. Additionally, she was one of the first executives at Castlight Health and later managed the company’s IPO in 2014. At Castlight Health, Nita led the company’s early sales efforts and later ran strategy, business development, corporate development and investor relations. Most recently, she was President of Honor, where she was responsible for all aspects of growth including sales, marketing, customer success, business development and corporate development. In addition to her work at start-ups, she also spent several years consulting with McKinsey’s health care practice and working across a number of healthcare industry sectors while with McKesson.Nita enjoys working with early stage companies on growth strategy and execution, including product strategy, commercial strategy, sales management, business development and organizational development. Nita has an M.B.A. from Stanford Graduate School of Business and a B.A. from Harvard University.In this episode we discussed:• Nita’s experience leading, exiting, and advising first-wave (1990s: athenahealth), second wave (2000s: Castlight) and third+ wave (2010+: Honor, others) digital health companies spanning three decades of health tech• What we can learn from these companies’ ascent, as history repeats itself: finding unmet need in a large market, narrowing in on a core set of business challenges, and proving value, not just scaling for scale’s sake• What makes the Operating Partner role unique in venture capital, and why her position at Khosla Ventures is distinctive across the healthcare fundraising landscape• Tactical advice to women on breaking the glass ceiling as an executive or venture partner

46mins

20 Jan 2021

Most Popular

Episode artwork

How Khosla Ventures Invests In Deep Tech, with Kanu Gulati and Rajesh Swaminathan

Deep Tech: From Lab to Market with Benjamin Joffe

Khosla Ventures (KV) has been an active investor in deep tech for 15 years. In this episode they share ideas on how they select sectors to invest in and prioritize and retire risk, how to best support startups, and what investors need to enter the deep tech field (hint: it's not a PhD). This podcast is hosted by Benjamin Joffe, Partner at SOSV, a global early stage fund focused on deep tech. SOSV runs multiple accelerator programs including HAX (intelligent hardware) and IndieBio (life sciences). To hear about new episodes, sign up to the newsletter or follow us on twitter at @LabToMarket. OVERVIEW Kanu Gulati and Rajesh Swaminathan are Investment Partners focused on deep tech at Khosla Ventures. The firm was founded by Vinod Khosla -- co-founder of Sun Microsystems (acquired by Oracle for US$7.4 billion in 2009) and former General Partner at Kleiner Perkins -- with the goal of ‘Reinventing Social Infrastructure with Technology’, to elevate the entire planet’s quality of life without destroying it. Over the past 15 years, KV has raised over $5B across 6 funds and invested in about 400 startups including Impossible Foods, Rocket Lab, DoorDash, OpenAI and many more.  They invest mostly at early stage — signing checks ranging from a few hundred $k, up to $50 million — and without shying away from the high technical risk of deep tech. After an introduction and examples from KV’s portfolio, the conversation goes into: Why it is crucial to prioritize risks and retire them in the right order. The 12 different technologies that can move the needle for the climate crisis. Their approach to detecting startups from centers of excellence. What sectors KV focuses on, including climate tech, hyperlocal and bio-manufacturing, hardware acceleration for AI, and more. What investment and operating partners do. How they support their portfolio in particular with recruiting (white paper). Vinod Khosla even calls himself a ‘glorified recruiter’! How conviction, immersion, patience and staying power matter more than a PhD to start investing in deep tech. How more engagement between financial and corporate VCs, building more forums and reducing inefficiencies in the deep tech ecosystem could help. PREVIOUS EPISODES Phil Morle (Main Sequence Ventures) on Australia's Deep Tech Ambitions Habib Haddad and Calvin Chin (E14 Fund of MIT Media Lab) on Funding Science Fiction That Works Robert Gallenberger (btov Partners) on How to Select Industrial Partners Xavier Duportet (Eligo Bioscience & Hello Tomorrow) on Science Entrepreneurship Deep Tech Startups vs. Covid-19, with IndieBio, Khosla Ventures and 50 Years Eric Rosenblum (Tsingyuan Ventures) on Chinese Founders in the US Overview of Deep Tech Investment, Based on the Report by Different Sota Nagano (Abies Ventures) on Japan’s Deep Tech Scene Seth Bannon (Fifty Years) on Solving Global Problems Kelly Chen (DCVC) on Investing in Old School Industries Manish Singhal (pi Ventures) on India’s Deep Tech Scene John Ho (Anzu Partners) on Breakthrough Industrial Tech Matt Clifford (EF / Entrepreneur First) on Investing in Talent and Pre-Product RESOURCES ON DEEP TECH DeepTech Investing Report by Different The Dawn of the Deep Tech Ecosystem by Hello Tomorrow and BCG Deep Tech Investors Mapping by Hello Tomorrow Deep Tech Trends Report, Hardware Trends Reports and Hardware Investment Outlook by SOSV SUBSCRIBE Podcast: Apple Podcast, Spotify, other platforms Twitter: @LabToMarket Lab to Market Newsletter

37mins

23 Aug 2020

Episode artwork

Deep Tech Startups vs Covid-19 with Khosla Ventures, Fifty Years and SOSV

Deep Tech: From Lab to Market with Benjamin Joffe

This is a a live panel ran by SOSV to introduce and discuss solutions funded by some of the most active investors in deep tech startups fighting Covid-19. Each of the three funds (Fifty Years, Khosla Ventures, SOSV) published an impressive list of their relevant portfolio startups. IndieBio even made a call to fund Covid-fighting startups as part of its newly launched NYC program. Here are the full video and slides. If you’d like to know about future events, follow us on Twitter at @SOSV or sign up to our newsletter. This podcast is hosted by Benjamin Joffe, Partner at SOSV, a global early stage fund focused on deep tech with over $700m under management. SOSV runs multiple accelerator programs, including HAX (intelligent hardware) and IndieBio (life sciences). Episode Overview This recording has 3 parts: Part 1: Some non-biotech solutions, from 3D printing to robotics, Part 2, VCs present solutions from their portfolio (mostly biotech), Part 3: Q&A. The speakers are: Seth Bannon, Founding Partner at Fifty Years, Alex Morgan, MD PhD, Partner at Khosla Ventures, Jun Axup, PhD, Partner at IndieBio (SOSV). Introduction & Moderation: Benjamin Joffe, Partner at SOSV Julie Wolf, PhD, Communications Director at IndieBio NYC (SOSV) Part 1 Introduction by Benjamin Joffe, Partner at SOSV a. What has changed since SARS? SARS was in 2003. In the span of 17 years, several important developments happened: Low-cost genetic tests Sensors & robots Cloud solutions The challenge of current solutions remain costs, timing and scalability. b. Prevention A hundred years ago, prevention was mostly... masks. Today, we have a much better understanding of the modes of infection of viruses, and many new tools to prevent it. c. 3D Printing While we’re still far from the ‘3D printing revolution’ that was announced 10 years ago, some high-resolution 3D printing technology is able to supply useful parts quickly, at low cost, and on-site. Clips and buckles for masks or door handles but also test swabs. d. Protecting our face We need to protect our face from others, but also from ourselves: Many masks don’t effectively protect against infection as the virus is too small (about 120nm). Verdex (a SOSV portfolio company) has developed a nanofiber material that filters out particles above 100nm — effectively blocking the virus — and is also more breathable. HabitAware, a HAX portfolio company, had created a machine-learning-powered bracelet to prevent body-focused repetitive behaviors (e.g. nail biting) by recognizing and alerting of specific gestures. The pandemic provided a new direct application of their technology. e. Disinfecting everything The ‘new normal’ is making frequent and thorough disinfection of our living and working environment necessary, to protect us and helps us get back to work. HAX has invested in various solutions for this, from floor cleaning (Avidbots) to toilet cleaning (Somatic). The dry cleaning robot startup Presso announced its solution initially intended for business travels was now in high-demand with movie and TV studios who are resuming operations. Youibot, an autonomous logistics startup, managed to repurpose their technology to provide disinfection with UV-C lights, and temperature detection. f. Testing with devices On the testing front, several countries have introduced testing stations that look like phone booths. Some are also using helmets with IR sensors to detect potential infections. Some wearable device companies like Oura and Strados Labs are applying their technology to pre-symptom detection or monitoring. g. Treatment Treating the virus is complicated, as it might also involve treating the immune response, and support the recovery of patients. Various large and small companies are working on vaccine candidates, Some companies are trying to develop new drugs, or repurpose existing ones for a faster time-to-market The lack of equipment — particularly respirators — is being addressed partly by repurposing other devices. Among them are snorkeling masks and BIPAP/CPAP machines. Finally, alongside this pandemic comes tremendous emotional harm due to stress, economic uncertainty and unemployment. Some companies such as Feel are working on low-cost solutions to help people improve their mental health. Part 2 Seth Bannon, Founding Partner at Fifty Years The Covid-19 threat is reminiscent of WWII, with potential deaths in the tens of millions. WWII gave us many tech innovations such as: mass production of antibiotics, blood plasma as a therapeutic solution, skin grafts, flu vaccine, radar, microwave ovens, pressurized plane cabins, nuclear power and the first programmable digital computer. It laid the foundation of technical progress for many years to come. A similar rally today could build solutions for the future. Everyone who can help should help, and 17 of our portfolio companies did. HelixNano (from the George Church lab at Harvard). Working on a vaccine to counteract SARS-Cov-2 evolutions and antigenic drift. BillionToOne found a way to run a test on Sanger sequencers at low cost and high volume. Opentrons (a co-investment with Khosla and SOSV) built a low-cost lab robot to automate liquid handling, already deployed in multiple labs around the world to test covid. Voodoo Manufacturing directed their cloud farm of 3D printers to focus on combating Covid-19 by producing PPE and more at cost. Solugen, that makes hydrogen peroxide, realized they had the capacity to make hand sanitizer and now do so pro-bono. Alex Morgan, Partner at Khosla Ventures Khosla has over $1B under management, including a main and seed fund. The goal is to ‘reinvent social infrastructure with technology’, looking for investments combining financial returns with societal impact (e.g. Impossible Foods, Color, etc.). We also have a list of companies responding to Covid-19. Genalyte has a FDA-approved testing solution that takes 15min. Current capacity is about~250k patients / month. Luminostics designed an optical test that cane be run with a small device attached to a phone. Pardes Bio is a recent investment working on a therapeutic using a protease inhibitor. Prellis Biologics (IndieBio/SOSV co-investment) is a tissue engineering company that can 3d print lymph nodes ex vivo to produce therapeutic antibodies (here are a recent video interview and media coverage). Some other investments also focus on the distribution of care, and particularly mental health, such as Ginger (remote service for mental health) and Flow Neuroscience (a SOSV/HAX co-investment offering a drug-free treatment for depression using an at-home brain stimulation device, already on sale in EU/UK). Jun Axup, Chief Science Officer & Partner at IndieBio IndieBio is the life sciences accelerator program of SOSV, based in SF and NYC and investing globally. It invested in 136 companies including Memphis Meats, Clara Food and Perfect Day in the cellAg space. CASPR Biotech uses CRISPR for low-cost testing (covered by NYT). Renegade.Bio was founded as a lab to test at high speed and large volume. ANA Therapeutics is repurposing an anti-worm treatment toward Zika, SARS and now Covid. Halomine found a way to keep surfaces free of viruses by stabilizing chlorine, making the protective film last up to 30 days instead mere hours. SmartSteward can track outbreaks within nursing homes, using algorithms to scan metadata from electronic health records and lab reports in real time, identifying critical changing patterns. The biotech renaissance is strong, but still has many unknowns: Are pandemics a new investable thesis? How do we get back to work, protect everyone? We need to stay nimble, and keep evolving. Part 3 Q&A moderated by Julie Wolf, Communications Director at IndieBio Q: How did IndieBio decide to invest in Covid solutions? Jun Axup (IndieBio/SOSV): Several are alumni who pivoted (e.g. Prellis), some simply needed more funding (e.g. Caspr.bio), some were opportunistic investments and some more philanthropic. The key was to fund companies who could have impact now rather than in a year. Q: For Khosla's startups, are pivots to Covid risky? Alex Morgan (Khosla Ventures): It varies a lot. Ideally we want to see long-term opportunities. Prellis, for example, are seizing an opportunity within a long-term plan. One challenge for diagnostic technologies is how you get paid, which is exposed to regulatory or policy risks. The landscape is changing and susceptible even to the election cycle. The current situation that delayed many procedures and treatments might push for a ‘pay for outcome’ model, which is more aligned with our investment model and the interests of patients. Q: How is 50Y looking at investing into Covid-related tech? Seth Bannon (Fifty Years): First, we offered a $25,000 uncapped note no questions asked to support any of our portfolio company who felt they had some kind of solution. For those needed more capital we had longer conversations. For new investments we don’t want to fund ‘covid-only’ solutions because it might be too difficult to build a business around, but most likely have applications beyond this pandemic, or beyond pandemics in general. For instance companies building infrastructure solutions, or take vaccine development from years to months, or found better ways to repurpose drugs. We’d love to see a great solution for at-home testing, maybe something CRISPR-based. Q: What is your biggest challenge in finding companies to invest in? Jun Axup (IndieBio/SOSV): Deployment and scaling is the hardest. We fund super early companies and getting through both regulations and manufacturing is a challenge, so we prefer teams that have some understanding of how to do that. Alex Morgan (Khosla Ventures): There is a lack of backchannel conversations that are not happening because [because of SIP/WFH], which could help find out about new companies or research. We’re trying with other media. Seth Bannon (Fifty Years): Because of the many solutions being developed, it is a challenge to find solutions that are uniquely suited to the pandemic, and whose solution and business would outlast it. Thanks to our speakers for their insights and to our audience for great questions! Speakers can be contacted at Twitter: Jun Axup (@junaxup, @indbio, @SOSV), Alex Morgan (@genomicsdoc or @khoslaventures) Seth Bannon (@sethbannon or @fiftyyears). Some of the remaining questions are on Twitter for further discussion. Resources Video and slides of the event. 50Y companies tackling the novel coronavirus SARS-CoV-2 Khosla Ventures’ entrepreneurs are responding with amazing diversity to COVID-19 solutions for society’s needs Top SOSV Startups Combatting COVID-19 IndieBio Coronavirus Initiative Previous Episodes Eric Rosenblum (Tsingyuan Ventures) on the Chinese Tech Diaspora Opportunity  Overview of Deep Tech Investment, Based on the Report by Different Sota Nagano (Abies Ventures) on Japan’s Deep Tech Scene Seth Bannon (Fifty Years) on Solving Global Problems Kelly Chen (DCVC) on Investing in Old School Industries Manish Singhal (pi Ventures) on India’s Deep Tech Scene John Ho (Anzu Partners) on Breakthrough Industrial Tech Matt Clifford (EF / Entrepreneur First) on Investing in Talent and Pre-Product Subscribe Podcast: Apple Podcast, Google Podcast, Spotify, etc. Twitter: @LabToMarket

45mins

8 Jun 2020

Episode artwork

#20: Irene Au (Khosla Ventures, Google) on scaling design teams and practices, scaling yourself and finding your why

Progression Podcast

About Irene Irene is a designer and veteran design leader, leading design and user experience at Google, Yahoo, Netscape, and Udacity. She was once even the most prolific hirer of UX talent in silicon valley.  She now works as an operational partner at Khosla Ventures, working with fast growing portfolio companies on design and strategic problems at the highest level, as well as teaching yoga. Our conversation covered scaling design across some of the most well known and iconic companies in the world as well as extrinsic vs intrinsic motivation, using envy to identify what you enjoy and finding the thing that gives you joy. I loved this conversation – Irene absolutely (but politely) schooled me on some of my assumptions about the evolution of design and I learned a ton. I hope you do too! Irene's website: ireneau.com Irene on Twitter: twitter.com/ireneau Design your Life – Irene's medium blog: https://medium.com/design-your-life Who else should we be speaking to? Be on the pod! Tell us about someone great! Just email podcast@progressionapp.com and tell us more. Our lovely sponsor: Deliveroo Our wonderful sponsor Deliveroo is looking for loads of designers, researchers, writers as well as leaders and managers. Go check them out at https://deliveroo.design We're looking for new sponsors! hit us up: podcast@progressionapp.com Join the waitlist We’re aiming to launch soon, but if you want to jump the gun or just be in the loop, get involved in our waitlist. progressionapp.com Rate us! It really helps if you rate us on iTunes. You can do that right here. https://podcasts.apple.com/gb/podcast/progression-podcast/id1435509539

41mins

28 Jan 2020

Episode artwork

20VC: Khosla Ventures Founding Partner, Samir Kaul on Why Pro Rata Is A Cop Out, Why He Likes Technical Risk and Does Not Take Market Risk & How To Approach Time Allocation Across The Portfolio In Venture

The Twenty Minute VC: Venture Capital | Startup Funding | The Pitch

Samir Kaul is a Founding Partner and Managing Director at Khosla Ventures, one of the valley's most renowned firms of the last decade with a portfolio including Square, Affirm, DoorDash, Impossible Foods and OpenDoor just to name a few. As for Samir, he led the firm's investment in Guardant Health, Impossible Foods, Nutanix [NASDAQ: NTNX], Oscar, among others. Prior to Khosla, Samir spent five years at Flagship Ventures where he started and invested in early-stage biotechnology companies, including Helicos Biosciences which went on to IPO. Samir was also founding CEO of Codon Devices and led the Arabidopsis Genome Initiative at Craig Venter’s Institute for Genomic Research. In Today’s Episode You Will Learn: 1.) How Samir made his way into the world of venture from the world of biotech and came to found one of the leading firms of the last decade? 2.) How did seeing the booms and busts of the last 2 decades impact Samir's investing mindset? Why does Samir think it is dangerous for a VC to have a "conservative mindset"? How does Samir analyse and think about upside maximisation when investing today? How does Samir think about when to sell your position and how to determine the right time? 3.) What does investment decision-making look like at Khosla? What are the criteria that re-investments are made upon? Why does Samir believe that pro-rata is a kop out? Which should be the core questions that determine whether to double down or not? How does Samir and the partnership think about time allocation across the portfolio? 4.) How does Samir approach the exercise of market sizing? Why does Samir never want to take a risk when it comes to market? Why does Samir want to maximise his risk when it comes to technological risk? How does Samir think through having to carry these deep tech companies for longer? What were his learnings from the clean tech days on this? 5.) How would Samir analyse his own price sensitivity today? What was his most formative inflexion moment as an investor? What did he learn from it? From a people side, who had the biggest impact on Samir as an investor? What were the core elements he learned from them? How does Samir deal with the element of self-doubt? How does he get through those moments? Items Mentioned In Today’s Show: Samir’s Fave Book: Start Something That Matters Samir’s Most Recent Investment: Lightship: Direct to Patient Clinical Trials  As always you can follow Harry, The Twenty Minute VC and Samir on Twitter here! Likewise, you can follow Harry on Instagram here for mojito madness and all things 20VC.

37mins

13 Jan 2020

Episode artwork

Ben Ling of Bling Capital (prev. Khosla Ventures), shares strategies from 100+ investments & 9 unicorns, qualities of great founders & teams, startup valuations, market opportunities, Google's early days, future of AR/VR | Angel S3 E6

Angel | hosted by Jason Calacanis

Ben Ling of Bling Capital (prev. Khosla Ventures), shares strategies from 100+ investments & 9 unicorns, qualities of great founders & teams, assessing market opportunities, the art of startup valuations, Google's early days, the future of AR/VR, & lessons from leading change in consumer behavior

56mins

27 May 2019

Episode artwork

Why Building a Startup is Hard with Keith Rabois, Khosla Ventures

Dorm Room Tycoon (DRT)

In this interview, Keith Rabois explains the importance of hard work and turning your startup into a smooth machine. We discuss management styles, the downfall of remote working and how to go about hiring talented people.

44mins

22 Apr 2018

Loading